Abstract
Background and Objectives
Macitentan is a potent, orally active, non-peptide antagonist of endothelin receptors with tissue-targeting properties, currently undergoing clinical development for the treatment of pulmonary arterial hypertension. The formation of its active metabolite, ACT-132577, as well as overall elimination of the drug, is catalyzed by the cytochrome P450 (CYP) system, predominantly CYP3A4 and to a lesser extent CYP2C19 isoenzyme. Macitentan is not a substrate of P-glycoprotein. Hepatic uptake is mostly driven by passive diffusion and is not dependent on organic anion-transporting polypeptide transport. This study aimed to investigate the magnitude of a possible effect of a potent CYP3A4 inhibitor, ketoconazole, on the pharmacokinetics of macitentan.
Methods
In a two-period, randomized, open-label, crossover study, 10 healthy subjects received each of the following treatments: Treatment A in which a single oral dose of 10 mg macitentan was administered on day 1 and Treatment B which consisted of initial daily treatment with ketoconazole 400 mg for 4 days, coadministration of macitentan and ketoconazole on the fifth day and continued administration of ketoconazole for 19 additional days.
Results
In the presence of ketoconazole, the exposure to macitentan expressed as area under the plasma concentration–time curve was increased by approximately a factor of 2 and to ACT-132577 was reduced by approximately 26 %.
Macitentan was well-tolerated with or without ketoconazole in this study and no relevant differences in safety parameters between the treatments were observed.
Conclusions
Although macitentan metabolism is indeed affected by CYP3A4 inhibition, the changes are not considered to be clinically significant and macitentan can be administered concomitantly with CYP3A4 inhibitors without need for dose adjustment.
Similar content being viewed by others
References
Kedzierski RM, Yanagisawa M. Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol. 2001;41:851–76.
Barton M, Yanagisawa M. Endothelin: 20 years from discovery to therapy. Can J Physiol Pharmacol. 2008;86(8):485–98.
Bolli MH, Boss C, Binkert C, et al. The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N′-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist. J Med Chem. 2012;55(17):7849–61.
Raja SG. Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis. Curr Opin Investig Drugs. 2010;11(9):1066–73.
Rubin L, Pulido T, Channick R. Effect of macitentan on morbidity and mortality in pulmonary arterial hypertension (PAH): Results from the SERAPHIN trial (Abstract). Chest. 2012;142:1026A.
Kummer O, Haschke M, Hammann F, et al. Comparison of the dissolution and pharmacokinetic profiles of two galenical formulations of the endothelin receptor antagonist macitentan. Eur J Pharm Sci. 2009;38(4):384–8.
Iglarz M, Binkert C, Morrison K, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther. 2008;327(3):736–45.
Weiss J, Theile D, Ruppell MA, et al. Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro. Eur J Pharmacol. 2013;701(1–3):168–75.
Gatfield J, Mueller Grandjean C, Sasse T, et al. Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. PLoS One. 2012;7(10):e47662.
Sidharta PN, van Giersbergen PL, Halabi A, et al. Macitentan: entry-into-humans study with a new endothelin receptor antagonist. Eur J Clin Pharmacol. 2011;67(10):977–84.
Bruderer S, Aanismaa P, Homery MC, et al. Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist. AAPS J. 2012;14(1):68–78.
Sidharta PN, van Giersbergen PL, Wolzt M, et al. Lack of clinically relevant pharmacokinetic interactions between the dual endothelin receptor antagonist macitentan and sildenafil in healthy subjects. Am J Respir Crit Care Med. 2012;185:A4802.
Bruderer S, Hopfgartner G, Seiberling M, et al. Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans. Xenobiotica. 2012;42(9):901–10.
Sidharta P, Lindegger N, van Giersbergen P, et al. Single-dose pharmacokinetics, safety, and tolerability of macitentan, a new dual endothelin receptor antagonist, in subjects with mild, moderate, or severe hepatic impairment. (Abstract). Chest. 2012;142:826A.
Sidharta P, Lindegger N, Ulč I, et al. Single-dose pharmacokinetics, safety, and tolerability of macitentan, a new dual endothelin receptor antagonist, in subjects with severe renal function impairment. (Abstract). Chest. 2012;142:830A.
FDA. Guidance for industry: drug interaction studies—study design, data analysis, implications for dosing and labeling recommendations. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf. Accessed 26 Mar 2013.
van Giersbergen PL, Halabi A, Dingemanse J. Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole. Br J Clin Pharmacol. 2002;53(6):589–95.
Richards DB, Walker GA, Mandagere A, et al. Effect of ketoconazole on the pharmacokinetic profile of ambrisentan. J Clin Pharmacol. 2009;49(6):719–24.
Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet. 2000;38(2):111–80.
Julious SA, Debarnot CA. Why are pharmacokinetic data summarized by arithmetic means? J Biopharm Stat. 2000;10(1):55–71.
Sidharta PN, Dingemanse J. Multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist ACT-064992 in healthy human subjects (Abstract). J Clin Pharmacol. 2008;48:1114.
Honig PK, Wortham DC, Zamani K, et al. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA. 1993;269(12):1513–8.
Dieterle W, Mann J. Pharmacokinetic interaction between ketoconazole and SPP301 in healthy volunteers. Int J Clin Pharmacol Ther. 2006;44(7):326–30.
Boxenbaum H. Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: determination of Ki and dangers associated with high clearance drugs in general. J Pharm Pharm Sci. 1999;2(2):47–52.
Chaikin P, Gillen MS, Malik M, et al. Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects. Br J Clin Pharmacol. 2005;59(3):346–54.
Product Information: CLARITIN® tablets, syrup, and rapidly-disintegrating tablets. Kenilworth: Schering Corporation; 2000.
Abel S, Russell D, Taylor-Worth RJ, et al. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol. 2008;65(Suppl 1):27–37.
Product Information: SELZENTRY® (maraviroc tablets). Research Triangle Park: ViiV Healthcare; 2012.
Grub S, Bryson H, Goggin T, et al. The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients. Eur J Clin Pharmacol. 2001;57(2):115–21.
Product Information: INVIRASE® (saquinavir mesylate) capsules and tablets for oral use. South San Francisco: Genentech Inc.; 2012.
Jeong S, Nguyen PD, Desta Z. Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A. Antimicrob Agents Chemother. 2009;53(2):541–51.
Acknowledgments
This study was sponsored by Actelion Pharmaceuticals Ltd. Ms Sidharta and Dr Dingemanse are full-time employees of Actelion Pharmaceuticals Ltd, and are entitled to stocks and stock options. Dr Atsmon was the principal investigator in this study. Drs Shaikevich and Volokh were co-investigators of this study. Drs Atsmon, Shaikevich and Volokh declared no conflicts of interest that are directly relevant to the content of this study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Atsmon, J., Dingemanse, J., Shaikevich, D. et al. Investigation of the Effects of Ketoconazole on the Pharmacokinetics of Macitentan, a Novel Dual Endothelin Receptor Antagonist, in Healthy Subjects. Clin Pharmacokinet 52, 685–692 (2013). https://doi.org/10.1007/s40262-013-0063-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40262-013-0063-8